CooperVision reveals new MiSight research data
CooperVision has disclosed new clinical trial data for its MiSight 1 day myopia contact lens, showing no rebound in children myopia one year after cessation of treatment. After six years of clinical trial using MiSight 1 day, study participants were transitioned to single vision lens in order to measure whether ...
To continue reading this article register now.
Already an Eyewear Intelligence subscriber? Sign in here.
Become a member today for full access from just €7,29 a week!
Buying a membership today will give you:
- Unlimited access to ewintelligence.com - all insight and analysis available online
- Our executive edition of Eyewear Intelligence (Digital Edition) - the must-read for all decision-makers in the industry
- Weekly E-mail Briefing from the Chief Editor with the lastest analysis and most important industry developments
- Case studies and best practices on business challenges
- Guest chronicles, interviews, insights from industry experts and leaders that are shaping the future of the industry
- Access to over 11,500 articles and analyses in the archive
- Personal library to save articles and track your key content
- Powerful search and intuitive navigation
Or sign-up for a trial month for just 9,90€. To continue reading this article register now.